Glatiramer: all 38 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMTTerminatedNCT03368664Phase 3Results posted
• Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®CompletedNCT02499900Phase 4Results posted
• Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)CompletedNCT02153723Phase 2Results posted
• An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)TerminatedNCT01578785Phase 3Results posted
• Efficacy and Safety of GTR in Comparison to Copaxone®CompletedNCT01489254Phase 3Results posted
• Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) PatientsCompletedNCT01167426Phase 3Results posted
• Treatment Interruption of NatalizumabCompletedNCT01071083Phase 2Results posted
• A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to PlaceboCompletedNCT01067521Phase 3Results posted
• Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)CompletedNCT00937157Not applicableResults posted
• A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)CompletedNCT00856635Phase 3Results posted
• Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple SclerosisCompletedNCT00811395Phase 2Results posted
• Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated SyndromeCompletedNCT00666224Phase 3Results posted
• Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).CompletedNCT00337779Phase 3Results posted
• Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00326625Phase 2Results posted
• Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRxCompletedNCT00211887Phase 3Results posted
• Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and EffectivenessCompletedNCT00203021Phase 4Results posted
• Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRICompletedNCT00176592Phase 4Results posted
• Asses the Anti-inflammatory Effects of Short Term Copaxone Therapy on Patients the Acute Decompensated Heart FailureCompletedNCT06003972Phase 2
• A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible TumorsActive, not recruitingNCT03982212Phase 1
• Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMSActive, not recruitingNCT03535298Phase 4
• Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis PatientsCompletedNCT03315923Phase 2/3
• Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple SclerosisCompletedNCT02753088Phase 3
• An Open Label, Exploratory Study to Investigate the Treatment Effect of Glatiramer Acetate on Girls Woth Rett SyndromeStatus unknownNCT02023424Phase 1
• Investigating the Neuroprotective Effect of Cop-1 (Copaxone) in Acute Primary Angle ClosureStatus unknownNCT01936129Phase 3
• High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple SclerosisWithdrawnNCT00939549Phase 2
• Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS)Status unknownNCT00910598Phase 4
• A Double Blind Placebo Control Study to Assess the Safety,Tolerability and Efficacy of Copaxone in Crohn's DiseaseStatus unknownNCT00731172Phase 2
• Effects of Copaxone in the Retinal Function in Diabetic Patients After PanphotocoagulationStatus unknownNCT00677664Phase 4
• Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-related Macular DegenerationSuspendedNCT00541333Phase 1
• Copaxone in Age Related Macular DegenerationStatus unknownNCT00466076Phase 2/3
• Gait Evaluation in Multiple Sclerosis Patients Treated With Glatiramer AcetateStatus unknownNCT00331747Not applicable
• FOCUS Fatigue Outcome in Copaxone USersCompletedNCT00267319Phase 4
• A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone®CompletedNCT00239993Phase 4
• Safety and Efficacy Study of Copaxone Administered in Combination With N-AcetylcysteineCompletedNCT00203099Phase 2
• A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.CompletedNCT00203073Phase 2
• Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMSTerminatedNCT00202995Phase 4
• A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved DoseCompletedNCT00202982Phase 2
• Phase III Randomized, Double-Blind, Placebo-Controlled Study of Copolymer 1 for Relapsing-Remitting Multiple SclerosisCompletedNCT00004814Phase 3

← Glatiramer overview